plantmad
vaccin
popular
innov
sourc
edibl
vaccin
number
edibl
crop
potato
tomato
lettuc
banana
corn
rice
use
express
antigen
variou
pathogen
includ
vibrio
cholera
enterotoxigen
escherichia
coli
etec
norwalk
viru
hepat
b
viru
human
anim
rotaviru
among
other
arntzen
rybicki
howev
although
initi
prospect
highli
attract
subsequ
research
identifi
problem
would
limit
advanc
use
plant
robust
platform
product
conveni
vaccin
perhap
main
modif
focu
obviou
need
introduc
process
vaccin
formul
ensur
plant
biomass
stabil
proper
dosag
vaccin
antigen
among
technolog
address
identifi
limit
use
bioreactor
biomass
product
allow
full
contain
product
process
freez
dri
partial
purifi
materi
use
seed
express
vehicl
order
yield
edibl
stabl
biomass
dosag
refin
express
system
higher
yield
allow
better
purif
formul
parenter
vaccin
yusibov
rabindran
et
al
develop
result
sophist
approach
current
make
adopt
plantbas
vaccin
pharma
industri
lot
like
previou
year
tabl
follow
section
present
exampl
plantderiv
biopharmaceut
adopt
industri
illustr
posit
impact
advanc
adopt
technolog
landri
et
al
penney
et
al
platform
propos
ideal
approach
produc
vaccin
quickli
critic
new
pandem
influenza
strain
virus
sarscov
merscov
estim
plantbas
vaccin
produc
transient
express
system
gener
within
week
releas
sequenc
inform
although
vaccin
eu
pharmaplanta
consortium
success
produc
topic
appli
antihiv
monoclon
antibodybas
microbicid
name
express
transgen
tobacco
plant
subject
phase
trial
carri
univers
surrey
clinic
research
centr
uk
particip
healthi
volunt
previou
studi
report
antibodi
capabl
recogn
cluster
highmannosetyp
nglycan
hiv
envelop
protein
lead
high
neutral
activ
vitro
vivo
sinc
prevent
transmiss
parenter
mucos
rout
mascola
veazey
et
al
tobacco
plant
n
tabacum
produc
grown
adequ
contain
greenhous
fraunhof
institut
molecular
biolog
appli
ecolog
ime
germani
fraunhof
present
result
clinic
trial
avail
investig
envisag
may
use
combin
plantproduc
antibodi
formul
broadli
protect
vagin
microbicid
pharmaplanta
exampl
constitut
first
plantderiv
biopharmaceut
approv
use
human
illustr
potenti
reach
marketplac
protalix
biotherapeut
carmel
israel
establish
product
human
recombin
glucocerebrosidas
suspens
cultur
transgen
carrot
cell
daucu
carota
l
therapeut
enzym
gaucher
diseas
lysosom
storag
disord
caus
mutat
human
glucocerebrosidas
gene
unlik
chines
hamster
ovari
cho
cellderiv
product
carrotderiv
enzym
termin
mannos
residu
glycan
allow
effici
uptak
via
macrophag
mannos
receptor
phase
iii
clinic
trial
complet
orphan
drug
design
grant
food
drug
administr
fda
product
current
approv
human
use
health
agenc
number
countri
protalix
case
mention
exemplifi
plantbas
platform
shown
suffici
degre
matur
develop
well
robust
lead
modal
product
find
nich
biopharmaceut
industri
clear
product
biopharmaceut
antibodi
enzym
prone
less
complex
evalu
case
vaccin
complex
paramet
achiev
longlast
immun
respons
capabl
support
immunoprotect
address
therefor
envis
vaccin
whose
target
antigen
immunogen
properti
convent
largescal
product
product
process
well
establish
first
plantbas
vaccin
produc
transient
system
impli
standard
approv
path
develop
biosimilar
influenza
viru
vaccin
case
highlight
potenti
howev
reluct
big
pharma
move
convent
product
platform
new
gener
still
hurdl
overcom
road
reach
market
plantbas
vaccin
deriv
substanti
exploit
technolog
still
long
one
follow
section
summar
perspect
identifi
basicresearch
regulatori
industri
level
pursu
goal
technic
innov
meet
regulatori
requir
promot
social
accept
parallel
polit
exploit
technolog
poor
countri
major
challeng
field
plantbas
vaccin
develop
modal
oral
immun
plant
biomass
high
potenti
attribut
immun
approach
simpl
needlefre
deliveri
low
cost
minim
process
plant
biomass
administ
vaccin
possibl
induc
mucos
respons
protect
oral
sexual
transmit
diseas
howev
sever
factor
need
address
success
elicit
safe
robust
immun
respons
oral
immun
assur
one
challeng
consist
elicit
robust
immun
respons
oral
rout
hamper
antigen
degrad
tolerogen
natur
system
fujkuyama
et
al
mestecki
et
al
sever
factor
may
impact
immunogen
oral
vaccin
among
formul
critic
aspect
gebril
et
al
case
plantbas
vaccin
propos
protect
effect
exert
plant
cell
wall
term
bioencapsul
effect
interestingli
number
studi
reveal
higher
immunogen
antigen
administ
form
plantderiv
prepar
rather
purifi
solubl
antigen
rosal
mendoza
et
al
hayden
et
al
pniewski
et
al
suggest
matrix
effect
may
associ
delay
degrad
rate
adjuv
effect
exert
plant
compound
otsuki
et
al
howev
realiti
systemat
studi
character
effect
conduct
report
focus
studi
bioavail
oral
plantbas
vaccin
effect
plant
tissu
use
express
immun
eg
pelosi
et
al
pelosi
et
al
thu
futur
evalu
effect
vaccin
formul
provid
new
insight
bioencapsul
effect
optim
immunogen
potenti
kind
vaccin
among
paramet
studi
particl
size
pillcapsul
composit
type
plant
tissu
administ
well
known
plant
synthes
complex
popul
metabolit
sometim
exert
profound
biolog
effect
plant
compound
recogn
immunomodul
follow
flavonoid
terpenoid
saponin
potterat
hamburg
et
al
schepetkin
quinn
plant
compound
also
act
mucoadhes
agent
account
effici
antigen
uptak
garg
et
al
thu
relev
research
object
field
would
character
specif
plant
compound
respons
enhanc
immunogen
plantderiv
formul
particular
relev
signific
challeng
field
oral
vaccin
consist
provid
appropri
adjuv
gener
accomplish
highcost
formul
anoth
concern
around
immunolog
event
associ
oral
vaccin
possibl
break
toler
toward
food
protein
present
plant
deliveri
vector
one
studi
focus
issu
publish
nojima
et
al
observ
humor
respons
rice
protein
elicit
rice
express
chimer
protein
compris
cholera
toxin
b
ctb
alzheim
diseaserel
antigen
oral
administ
mice
howev
author
hypothes
immunolog
toler
nontarget
rice
protein
could
induc
mean
breastfeed
therefor
immun
mice
subsequ
fed
lactat
mother
consum
rice
protein
led
success
induct
toler
suggest
design
specif
immun
scheme
potenti
modul
undesir
immun
respons
howev
field
investig
still
infanc
highlight
need
expand
evalu
target
immun
respons
challeng
experi
anim
model
also
address
question
regard
safeti
term
elicit
respons
nontarget
protein
systemat
research
direct
must
conduct
better
understand
immun
respons
elicit
plantbas
vaccin
could
modul
order
avoid
undesir
immun
respons
may
eventu
mediat
allerg
event
undesir
side
effect
although
current
express
strategi
consid
robust
term
yield
suitabl
industri
applic
certain
aspect
express
system
may
allow
innov
improv
formul
induct
broader
immun
respons
relev
goal
especi
case
hypervari
pathogen
eg
influenza
hiv
virus
one
approach
address
simultan
express
sever
antigen
singl
transform
transient
event
transplastom
technolog
use
use
polycistron
vector
allow
simultan
express
protein
see
modal
express
antigen
plant
plastidbas
express
strategi
addit
virusderiv
vector
may
allow
nuclear
express
approach
one
strategi
involv
use
intern
ribosom
entri
site
sequenc
ire
allow
translat
sever
open
read
frame
orf
via
capindepend
translat
ha
et
al
gouiaa
et
al
anoth
altern
use
picornavir
endopeptidas
sequenc
mediat
translat
skip
mechan
allow
product
differ
polypeptid
singl
orf
target
antigen
link
sequenc
halpin
et
al
ha
et
al
approach
remain
essenti
unexplor
field
consid
great
potenti
aid
improv
plantbas
vaccin
product
among
option
implement
process
full
contain
good
manufactur
practic
gmp
use
cell
suspens
organ
cultur
hairi
root
system
approach
offer
tightli
control
bioprocess
environ
concern
relat
undesir
gene
flow
elimin
franconi
et
al
michoux
et
al
skarjinskaia
et
al
addit
platform
implement
biopharmaceut
field
remain
explor
vaccin
product
particular
moss
physcomitrella
paten
propos
rosal
robust
platform
product
recombin
vaccin
nonvascular
plant
propag
filament
develop
stage
name
protonema
grown
liquid
media
use
bioreactor
approach
sever
singular
advantag
low
cost
wellestablish
product
system
platform
product
plantbas
vaccinesem
full
contain
product
effici
secret
antigen
media
facilit
purif
possibl
produc
specif
glycoform
use
strain
genet
engin
altern
glycosyl
machineri
explor
emerg
plant
product
platform
may
lead
innov
develop
exampl
product
immunogen
specif
glycosyl
pattern
improv
immunogen
properti
new
process
perform
full
contain
number
highli
relev
patholog
consid
vaccin
prevent
still
caus
signific
epidemiolog
impact
cost
gener
main
obstacl
widespread
vaccin
adopt
plantbas
technolog
develop
product
vaccin
expand
list
vaccin
prevent
diseas
repres
import
field
opportun
medic
biotechnolog
follow
section
describ
diseas
new
vaccin
urgent
need
constitut
logic
target
plantbas
vaccin
product
technolog
tropic
neglect
diseas
group
diseas
affect
live
billion
peopl
worldwid
vaccin
avail
vaccin
neglect
tropic
diseas
ntd
low
cost
prefer
needl
free
order
reduc
logist
cost
administr
although
number
effort
develop
vaccin
fight
rabi
cysticercosi
dengu
fever
helminthiasi
report
still
need
develop
plantbas
vaccin
model
group
develop
plantbas
vaccin
tropic
neglect
diseas
identifi
key
prioriti
exploit
technolog
lowcost
formul
may
produc
fight
diseas
mainli
impact
lowincom
popul
rosal
mendoza
et
al
noncommunic
diseas
patholog
kill
ten
million
peopl
high
fraction
death
occur
peopl
age
year
compris
product
human
cohort
incid
diseas
continu
rise
especi
lowand
middleincom
countri
particular
interest
combat
diseas
vaccin
cancer
hypertens
diabet
atherosclerosi
play
major
role
mortal
rate
global
level
accord
world
health
organ
lead
global
risk
mortal
high
blood
pressur
respons
death
global
tobacco
use
high
blood
glucos
physic
inact
overweight
obes
risk
respons
rais
risk
chronic
diseas
heart
diseas
diabet
cancer
type
diabet
autoimmun
diseas
target
number
group
use
plantbas
vaccin
model
propos
therapi
consist
elicit
toler
glutam
acid
decarboxylas
selfantigen
associ
develop
immun
respons
respons
diabet
develop
goal
pursu
administ
autoantigen
mucos
rout
tolerogen
natur
kind
approach
success
evalu
anim
model
promis
find
term
therapeut
effect
suggest
consider
potenti
clinic
trial
alvarez
et
al
langridg
et
al
immunotherapi
treatment
patholog
well
document
particular
vaccin
model
use
convent
formul
base
induct
humor
respons
physiolog
protein
whose
elev
level
favor
develop
patholog
bachmann
jen
howev
activ
immun
therapi
essenti
develop
human
cancer
repres
field
opportun
convent
chemotherapi
radiotherapi
lack
specif
show
signific
toxic
vaccin
propos
complementari
treatment
exampl
human
carcinoembryon
antigen
cea
overexpress
larg
number
epitheli
neoplasia
includ
colorect
carcinoma
crc
gastric
pancreat
breast
lung
ovarian
carcinoma
hammarstrom
consid
tumorassoci
antigen
target
therapeut
cancer
vaccin
berinstein
shown
safe
induct
antigenspecif
immun
respons
achiev
mosolit
et
al
samanc
et
al
thu
expect
focus
kind
target
signific
relev
field
plantbas
vaccin
spite
mani
candid
vaccin
antigen
express
plant
proven
effect
thu
far
candid
progress
beyond
preclin
phase
factor
limit
progress
market
elabor
chapter
interestingli
regulatori
framework
alreadi
establish
limit
growth
crop
plant
express
pharmaceut
includ
vaccin
develop
limit
use
exampl
maiz
rice
potato
tomato
food
commerci
vaccin
product
commerci
also
requir
facil
manufactur
vaccin
medium
larg
scale
current
gmp
streatfield
gmp
establish
constitut
associ
group
norm
activ
guarante
everi
product
meet
retain
characterist
design
requir
use
gmp
minim
unanticip
risk
may
occur
screen
final
product
van
der
laan
et
al
exampl
kentucki
bioprocess
llc
kbp
owensboro
ky
facil
special
express
extract
purif
recombin
protein
plant
bench
commerci
scale
use
proprietari
genewar
express
technolog
gmp
condit
yusibov
et
al
evalu
vaccin
tradit
method
follow
plantbas
vaccin
howev
plant
contain
particular
issu
product
type
vaccin
term
product
clinic
assess
plantbas
vaccin
must
appli
investig
new
drug
ind
applic
applic
regulatori
requir
yusibov
et
al
guidelin
contain
draft
document
defin
fda
us
depart
agricultur
usda
address
qualiti
aspect
product
plantbas
biopharmaceut
human
anim
use
present
point
relat
product
safeti
efficaci
environment
issu
manufactur
control
center
veterinari
medicin
et
al
particular
fda
establish
develop
stage
must
compris
evalu
presenc
potenti
allergen
toxic
compound
method
plant
product
propag
character
recombin
dna
genet
stabil
case
base
stabl
transform
event
environment
concern
taken
consider
mean
implement
confin
mechan
order
control
spread
bioengin
pharmaceut
plant
also
meet
regul
transnat
commerci
addit
facil
procedur
design
prevent
crosscontamin
sourc
materi
harvest
process
impli
establish
procedur
appropri
clean
mainten
sanit
equip
utensil
thu
malfunct
contamin
would
alter
safeti
ident
strength
qualiti
puriti
product
prevent
hand
test
presenc
ident
potenti
harm
constitu
requir
perform
preclin
trial
compris
toxin
pathogen
pesticid
herbicid
fungicid
heavi
metal
antinutri
allergen
assess
vitro
vivo
assay
addit
unintend
immunogen
due
plantspecif
posttransl
modif
must
assess
pass
clinic
trial
exist
guidelin
clinic
evalu
drug
biolog
human
consid
addit
special
advic
obtain
commun
regulatori
agenc
center
drug
evalu
research
fda
cder
center
biolog
evalu
research
fda
cber
center
veterinari
medicin
toxic
dose
lottolot
consist
possibl
allerg
respons
immun
toler
must
evalu
develop
plantbas
biopharmaceut
intend
commerci
howev
spite
inher
potenti
plant
bioreactor
robust
proof
would
provid
regard
efficaci
eas
deliveri
cost
stringent
regulatori
requir
human
product
veterinari
product
probabl
go
fastest
market
hammond
nemchinov
despit
fact
oral
vaccin
consid
advantag
immun
approach
approach
face
number
challeng
suitabl
dose
regimen
must
defin
vaccin
candid
formul
oral
vaccin
requir
gener
high
dose
antigen
turn
may
also
difficult
accur
determin
complex
gastrointestin
tract
see
mucos
immunolog
oral
vaccin
therefor
formul
deliveri
strategi
optim
attain
immunoprotect
accept
consist
streatfield
howard
also
consider
ethic
issu
plantbas
vaccin
subject
suffici
analysi
mani
ethic
social
debat
relat
genet
modifi
gm
plant
cover
topic
plantbas
vaccin
superfici
manner
howev
neg
percept
gm
food
may
fact
influenc
social
accept
plantbas
vaccin
main
reason
gm
food
wide
accept
civil
societi
percept
consumpt
carri
unknown
risk
major
beneficiari
farmer
seed
compani
final
consum
contrast
exampl
humanitarian
project
pharmaplanta
consortium
major
beneficiari
plantbas
vaccin
therapeut
patient
develop
poor
countri
howev
substanti
transfer
technolog
principl
benefit
definit
favor
posit
percept
technolog
hope
eventu
accept
interest
invest
pharmaceut
industri
seen
key
factor
benefit
plantbas
technolog
biopharmaceut
product
becom
realiti
last
two
decad
product
biopharmaceut
increas
notabl
period
biolog
approv
fda
biopharmaceut
approv
last
two
decad
total
biopharmaceut
product
approv
regulatori
agenc
treat
sever
human
diseas
goldstein
thoma
rader
wong
recombin
protein
produc
plant
found
preferenti
nich
biopharmaceut
field
rather
industri
product
enzym
polym
howev
pharmaceut
compani
complet
adopt
biopharmaceut
nextgener
drug
davi
molecular
farm
approach
technic
success
possess
potenti
implement
larg
scale
evidenc
mani
public
patent
field
test
studi
yield
posit
result
efficaci
trial
anim
evalu
clinic
trial
promis
insight
tiwari
et
al
yusibov
et
al
plantbas
vaccin
high
potenti
improv
global
health
although
depend
demonstr
efficaci
safeti
feasibl
commerci
pharmaceut
compani
philanthrop
organ
govern
develop
develop
countri
sadli
despit
promis
breakthrough
develop
oral
vaccin
far
due
partli
complex
approach
sustain
collabor
plant
scientist
immunologist
vaccinologist
consid
particular
import
maintain
advanc
develop
effect
costeffect
oral
vaccin
candid
requir
innov
research
goal
address
import
question
relat
safeti
strategi
improv
immunogen
also
signific
econom
resourc
public
nonprofit
organ
well
invest
industri
order
invigor
field
tiwari
et
al
notabl
vaccin
newcastl
viru
produc
suspensioncultur
tobacco
cell
line
dow
agrosci
india
success
test
purifi
inject
product
chicken
approv
usda
full
licensur
anim
usa
rybicki
melnik
stoger
advanc
approach
plantbas
human
vaccin
develop
medicago
inc
usa
canada
consist
influenza
candid
vaccin
target
season
season
influenza
landri
et
al
penney
et
al
medicago
inc
support
public
fund
need
order
advanc
develop
plantbas
vaccin
stage
corpor
investor
becom
involv
howev
also
necessari
evalu
clinic
trial
technolog
prove
worthi
major
disburs
fund
grant
target
particular
diseas
specif
locat
robert
kirk
outlook
develop
countri
envis
plantbas
biopharmaceut
industri
consolid
next
decad
recombin
protein
vaccin
includ
subunitbas
vlpbase
vaccin
good
candid
new
product
system
plantbas
pharmaceut
compani
respond
regulatori
requir
order
demonstr
plant
appropri
platform
product
davi
scotti
rybicki
realist
view
translat
compani
favor
financi
support
develop
vaccin
signific
market
thu
spite
achiev
significantli
preclin
level
consid
particular
relev
advanc
technolog
develop
countri
need
new
vaccin
diseas
great
neglect
larger
compani
humanitarian
focu
indispens
factor
open
path
exploit
plantbas
vaccin
exampl
pharmaplanta
consortium
establish
europ
order
promot
product
antihiv
microbicid
antibodi
candid
meet
regulatori
requir
gmp
standard
preclin
toxic
test
statement
intent
humanitarian
use
guarante
access
poor
countri
plantbas
product
develop
wwwpharmaplantanet
particular
relev
object
consortium
compris
develop
robust
riskassess
practic
plantmad
pharmaceut
base
health
environment
impact
collabor
regulatori
author
within
eu
public
group
guarante
safeti
accept
product
system
base
biosafeti
regul
design
implement
program
intend
secur
manag
intellectu
properti
thu
facilit
avail
highprior
plantderiv
recombin
pharmaceut
poor
countri
time
allow
product
develop
commerci
europ
north
america
exampl
illustr
kind
effort
may
allow
massiv
exploit
technolog
aid
overrid
valley
death
block
wider
use
technolog
humankind
benefit
obemb
et
al
envis
poor
develop
countri
must
establish
polici
favor
increas
connect
research
institut
univers
local
compani
even
govern
agenc
critic
factor
exploit
potenti
plantbas
vaccin
countri
need
lowcost
vaccin
great
urgent
novel
method
need
financ
increas
number
new
vaccin
potenti
save
live
countri
poor
afford
hefferon
levin
et
al
select
new
vaccin
prioriti
particular
countri
given
advic
conjunct
nation
immun
advisori
committe
adopt
plantbas
vaccin
could
necessit
modif
immun
schedul
deliveri
procedur
recent
suggest
develop
countryfirm
nongovernment
organ
concern
vaccin
manufactur
team
develop
countryscientist
institut
research
develop
well
clinic
trial
alreadi
indic
happen
exampl
fiocruzbiomanguinho
brazil
collabor
ibio
inc
usa
make
yellow
fever
viru
vaccin
use
plant
ventria
bioscienc
usa
grow
transgen
riceproduc
lactoferrin
lysozym
year
see
rybicki
et
al
kind
collabor
could
open
door
product
lowcost
vaccin
pharmaceut
need
use
local
scientif
commerci
resourc
would
welcom
chang
present
model
plantbas
product
evolv
robust
approach
manufactur
vaccin
condit
meet
requir
varieti
regulatori
system
benefit
deriv
technolog
expect
becom
evid
come
year
realiz
introduct
first
vaccin
market
nonvaccin
biopharmaceut
alreadi
market
indic
potenti
achiev
goal
short
term
interest
aspect
develop
oral
vaccin
repres
research
path
explor
detail
systemat
manner
order
acceler
develop
constitut
ideal
applic
plantbas
vaccin
due
easi
administr
low
cost
humanitarian
initi
pharmaplanta
consortium
identifi
key
strategi
attain
benefit
biofarm
develop
countri
futur
research
effort
expand
applic
technolog
new
targetrelev
diseas
also
key
import
exploit
wider
manner
advantag
plantbas
vaccin
